Copper deficiency as an anti-cancer strategy

Endocrine-Related Cancer

Volumn 11, Issue 2, 2004, Pages 255-263

  Goodman, V L ^a   Brewer, G J ^a   Merajver, S D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Medicinal Chemistry and Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; COPPER; FIBROBLAST GROWTH FACTOR; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRANSFORMING GROWTH FACTOR BETA; TRIENTINE; VASCULOTROPIN;

CANCER INHIBITION; CANCER INVASION; COPPER DEFICIENCY; HUMAN; MENKES SYNDROME; METASTASIS; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; WILSON DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; CHELATING AGENTS; COPPER; HUMANS; MOLYBDENUM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 3042680173     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110255     Document Type: Review

References (68)

1. Alessandri G, Raju K & Gullino PM 1984 Angiogenesis in vivo and selective mobilization of capillary endothelium in vitro by heparin-copper complex. Microcirculation, Endothelium and Lymphatics 1 329-346.
2. Badet J, Soncin F, Guitton J, Lamare O, Cartwright T & Barritault D 1989 Specific binding of angiogenin to calf pulmonary artery endothelial cells. PNAS 86 8427-8431.
3. Bendell-Young L, Chouinard J & Pick FR 1994 Metal concentrations in chironomids in relation to peatland geochemistry. Archives of Environmental Contamination and Toxicology 27 186-194.
4. Bikfalvi A & Bicknell R 2002 Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends in Pharmacological Sciences 23 576-582.
5. Borghouts C & Osiewacz HD 1998 GRISEA, a copper-modulated transcription factor from Podospora anserina involved in senescence and morphogenesis, is an ortholog of MAC1 in Saccharomyces cerevisiae. Molecular Genes and Genetics 260 492-502.
6. Borghouts C, Kimpel E & Osiewacz HD 1997 Mitochondrial DNA rearrangements of Podospora anserina are under the control of the nuclear gene grisea. PNAS 94 10768-10773.
7. Brem S, Tsanaclis AM & Zagzag D 1990a Anticopper treatment inhibits pseudopodial protrusion and invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 26 391-396.
8. Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP & Brien SE 1990b Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. American Journal of Pathology 137 1121-1142.
9. Brewer GJ 2001a Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Experimental Biology and Medicine 226 665-673.
10. Brewer GJ 2001b The Clinician's Challenge: Recognising Wilson's Disease. In Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis and Management pp 10-16. Boston: Kluwer Academic Publishers.
11. Brewer GJ & Yuzbasiyan-Gurkan V 1992 Wilson disease. Medicine 71 139-164.
12. Brewer GJ, Terry CA, Aisen AM & Hill GM 1987 Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Archives of Neurology 44 490-493.
13. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tankanow R, Young AB & Kluin KJ 1991 Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Archives of Neurology 48 42-47.
14. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK & Aisen A 1994 Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Archives of Neurology 51 545-554.
15. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK & Brunberg JA 1996 Treatment of Wilson's disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Archives of Neurology 53 1017-1025.
16. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G & Merajver SD 2000 Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clinical Cancer Research 6 1-10.
17. Bull PC, Thomas GR, Rommens JM, Forbes JR & Cox DW 1993 The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genetics 5 327-337.
18. Bunn PA Jr 2002 Molecular biology and early diagnosis in lung cancer. Lung Cancer 38 S5-S8.
19. Commission on Life Science 2000, Health Effects of Excess Copper. In Copper in Drinking Water, pp 78-127. Washington DC: National Academies Press.
20. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD & Merajver SD 2001 The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoseope 111 696-701.
21. Dancis A, Haile D, Yuan DS & Klausner RD 1994 The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. Journal of Biological Chemistry 269 25660-25667.
22. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF & Vallee BL 1985 Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells, Biochemistry 24 5480-5486.
23. Folkman J 1971 Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285 1182-1186.
24. Folkman J 1974 Tumor angiogenesis factor. Cancer Research 34 2109-2113.
25. Hall AC, Young BW & Bremner I 1979 Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. Journal of Inorganic Biochemistry 11 57-66.
26. Hanahan D & Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 353-364.
27. Hassett R & Kosman DJ 1995 Evidence for Cu(II) reduction as a component of copper uptake by Saccharomyces cerevisiae. Journal of Biological Chemistry 128-134.
28. Hu GF 1998 Copper stimulates proliferation of human endothelial cells under culture. Journal of Cellular Biochemistry 69 326-335.
29. Iruela-Arispe ML & Dvorak HF 1997 Angiogenesis: a dynamic balance of stimulators and inhibitors. Thrombosis and Haemostasis 78 672-677.
30. Kashin VK & Ivanoc GM 1999 Copper in Trasbaikal flora. Agrokhimiya 10 52-57.
31. Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, Van Golen K, Brewer GJ & Merajver SD 2002 Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4 164-170.
32. Kudashkin MI 2000 The content of different copper compounds in gray forest soils of Mordovia and effectiveness of preplanting treatment of barley seeds with copper sulfate. Agrokhimiya 3 16-24.
33. Labbe S, Zhu Z & Thiele DJ 1997 Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway. Journal of Biological Chemistry 272 15951-15958.
34. Landriscina M, Bagala C, Mandinova A, Soldi R, Micucci I, Bellum S, Prudovsky I & Maciag T 2001 Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor I in response to stress. Journal of Biological Chemistry 276 25549-25557.
35. Lesuisse E, Casteras-Simon M & Labbe P 1996 Evidence for the Saccharomyces cerevisiae ferrireductase system being a multicomponent electron transport chain. Journal of Biological Chemistry 271 13578-13583.
36. Linder MC, Houle PA, Isaacs E, Moor JR & Scott LE 1979 Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24 23-35.
37. McAuslan BR, Reilly WG, Hannan GN & Gole GA 1983 Angiogenic factors and their assay: activity of formyl methionyl leucyl phenylalanine, adenosine diphosphate, heparin, copper, and bovine endothelium stimulating factor. Microvascular Research 26 323-338.
38. Mandinov L 2003 Copper chelation represses the vascular response to injury. PNAS 100 6700-6705.
39. Menard MP, McCormick CC & Cousins RJ 1981 Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc. Journal of Nutrition 1351-1361.
40. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP & Reuter VE 1993 Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. Journal of the National Cancer Institute 85 1597-1599.
41. Olson KA, French TC, Vallee BL & Fett JW 1994 A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Research 54 4576-4579.
42. Olson KA, Byers HR, Key ME & Fett JW 2001 Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clinical Cancer Research 7 3598-3605.
43. Osiewacz HD & Nuber U 1996 GRISEA, a putative copper-activated transcription factor from Podospora anserina involved in differentiation and senescence. Molecular Genes and Genetics 252 115-124.
44. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ & Merajver SD 2002 Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Research 62 4854-4859.
45. Pan Q, Bao LW, Kleer CG, Brewer GJ & Merajver SD 2003 Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Molecular Cancer Therapeutics 2 617-622.
46. Parke A, Bhattacherjee P, Palmer RM & Lazarus NR 1988 Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. American Journal of Pathology 130 173-178.
47. Piccoli R, Olson KA, Vallee BL & Fett JW 1998 Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. PNAS 95 4579-4583.
48. Raju KS, Alessandri G, Zinche M & Gullino PM 1982 Ceruloplasmin, copper ions, and angiogenesis. Journal of the National Cancer Institute 69 1183-1188.
49. Ravestyn AH 1944 Metabolism of copper in man. Acta Medica Scandinavica 118 163-196.
50. Redman BG, Esper P, Dunn RL, Pan Q, Merajver SD, Hussain HK, Chenevert T & Brewer GJ 2003 Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clinical Cancer Research 9 1666-1672.
51. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R & Harris AL 1997 Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research 57 963-969.
52. Rybak SM, Fett JW, Yao QZ & Vallee BL 1987 Angiogenin mRNA in human tumor and normal cells. Biochemical and Biophysical Research Communications 146 1240-1248.
53. Scappaticci FA 2002 Mechanisms and future directions for angiogenesis-based cancer therapies. Journal of Clinical Oncology 20 3906-3927.
54. Sen CK, Khanna S, Venojarvi M, Trikha P, Ellison EC, Hunt TK & Roy S 2002 Copper-induced vascular endothelial growth factor expression and wound healing. American Journal of Physiology. Heart Circulation Physiology 282 H1821-H1827.
55. Soncin F, Guitton J, Cartwright T & Badet J 1997 Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochemical and Biophysical Research Communications 236 604-610.
56. Starosta-Rubinstein S, Young AB, Kluin K, Hill G, Aisen AM, Gabrielsen T & Brewer GJ 1987 Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Archives of Neurology 44 365-370.
57. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W & Ross B 1993 The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genetics 4 44-50.
58. Tebaldi FLH, da Silva JFC, Vasques HM & Thiebaut JTL 2000 Mineral composition of pastures in the North and Northwest regions of Rio de Janeiro State. 2. Manganese, iron, zinc, copper, cobalt, molybdenum and lead. Revista Brasileira de Zootecnia 29 616-629.
59. Toi M, Hoshina S, Takayanagi T & Tominaga T 1994 Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Japanese Journal of Cancer Research 85 1045-1049.
60. Walshe JM 1956 Penicillamine: a new oral therapy for Wilson's disease. American Journal of Medicine 487-495.
61. Walshe JM 1982 Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet i 643-647.
62. Watanabe T, Seno M, Sasada R & Igarashi K 1990 Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Molecular Endocrinology 4 869-879.
63. Winge DR 1999 Copper-regulatory domain involved in gene expression. In Copper Transport and its Disorders: Molecular and Cellular Aspects, Eds A Leone & JFB Mercer. New York: Kluwer Academic Publishers.
64. Yamaguchi Y, Heiny ME & Gitlin JD 1993 Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochemical and Biophysical Research Communications 197 271-277.
65. Yamaguchi-Iwai Y, Serpe M, Haile D, Yang W, Kosman DJ, Klausner RD & Dancis A 1997 Homeostatic regulation of copper uptake in yeast via direct binding of MAC1 protein to upstream regulatory sequences of FRE1 and CTR1. Journal of Biological Chemistry 272 17711-17718.
66. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, Tsujinoue H, Nakatani T, Kishida H, Nakae D, Gomez DE, De Lorenzo MS, Tejera AM & Fukui H 2001 The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. International Journal of Cancer 94 768-773.
67. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ & Brewer GJ 1992 Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. Journal of Laboratory and Clinical Medicine 120 380-386.
68. 1 and copper in angiogenesis. Journal of the National Cancer Institute 69 475-482.